CurcuminanimalAnimal model2000

Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats.

Japanese journal of cancer research : Gann

confidence

Key findings

Curcumin inhibited NMBA-induced esophageal carcinogenesis in both initiation and post-initiation phases, reducing neoplasm incidence/multiplicity and cell proliferation.

View source on PubMed (PMID 11011116) ↗

Sample size
5 groups of rats
Population
Male F344 rats with NMBA-induced esophageal carcinogenesis
Dosing
500 ppm curcumin in diet; NMBA 0.5 mg/kg/injection x15
Duration
Full experiment including 5-week initiation and post-initiation phases
Route
Oral (dietary curcumin); intraperitoneal (NMBA)
Blinding
not_reported
Controls
none
Drug class
polyphenol

Measured endpoints

  • Incidence of esophageal neoplasms (initiation phase)Decreasedcancer
    significanteffect: 39.3% vs 66.7%
  • Multiplicity of esophageal neoplasms (initiation phase)Decreasedcancer
    significanteffect: 0.46 ± 0.64 vs 0.83 ± 0.70
  • Incidence of esophageal neoplasms (post-initiation phase)Decreasedcancer
    significanteffect: 33.3% vs 66.7%
  • Multiplicity of esophageal neoplasms (post-initiation phase)Decreasedcancer
    significanteffect: 0.36 ± 0.56 vs 0.83 ± 0.70
  • Incidence of esophageal preneoplastic lesions (initiation phase)Decreasedcancer
    significanteffect: 57.1% vs 100%
  • Multiplicity of esophageal preneoplastic lesions (initiation phase)Decreasedcancer
    significanteffect: 0.61 ± 0.57 vs 1.67 ± 0.70
  • Incidence of esophageal preneoplastic lesions (post-initiation phase)Decreasedcancer
    significanteffect: 56.7% vs 100%
  • Multiplicity of esophageal preneoplastic lesions (post-initiation phase)Decreasedcancer
    significanteffect: 0.67 ± 0.66 vs 1.67 ± 0.70
  • Cell proliferation (BrdU labeling index) in non-lesional esophageal epitheliumDecreasedcancer
    significant
Full abstract

Modifying effects of curcumin (derived from the rhizome of Curcuma longa L.) during the initiation or post-initiation phase of N-nitrosomethylbenzylamine (NMBA)-induced esophageal carcinogenesis were investigated in male F344 rats. Five-week-old rats were divided into 5 groups, and groups 1, 2 and 3 were given intraperitoneal injections of NMBA (0.5 mg / kg body weight / injection 15 times) for 5 weeks from 7 weeks old to induce esophageal neoplasms. Groups 2 and 3 were fed the diet containing 500 ppm curcumin during the initiation and post-initiation phases, respectively. Group 4 was given the diet containing curcumin throughout the experiment, and group 5 was kept on the basal diet alone and served as an untreated control. Incidence and multiplicity of esophageal neoplasms of group 1 (NMBA alone) were 66.7% and 0.83 +/- 0.70, respectively. Those of groups 2 and 3 were significantly less than those of group 1 (39.3%, 0.46 +/- 0.64, P < 0.05; 33.3%, 0.36 +/- 0.56, P < 0.05, respectively). Furthermore, the incidence and multiplicity of esophageal preneoplastic lesions (moderate or severe epithelial dysplasia) of group 2 (57.1%, 0.61 +/- 0.57; 40%, 0.29 +/- 0.46) or 3 (56.7%, 0.67 +/- 0.66; 23.3%, 0.23 +/- 0.43) were less than those of group 1 (100%, 1.67 +/- 0.70; 70.8%, 0.92 +/- 0.72) (P < 0.05). In this experiment, feeding of curcumin significantly decreased the expression of cell proliferation biomarkers (5-bromo-2'-deoxyuridine labeling index) in the non-lesional esophageal epithelium (P < 0.01). These findings indicate that curcumin inhibits NMBA-induced esophageal carcinogenesis when given during the post initiation as well as initiation phase. This inhibition may be related to suppression of the increased cell proliferation induced by NMBA in the esophageal epithelium.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.